Clinical trials recruiting for Anatomic Stage III Breast Cancer AJCC v8

Phase breakdown

Drugs and treatments being studied

Where trials are recruiting (top US states)

Top cities

Self-screener

Recruiting trials

• 5-strain Probiotic Formulation in HR-positive Breast Cancer Receiving Aromatase Inhibitor to Prevent Bone Loss
  NCT07044310 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Female · 1 location
• A Blended e-Health Intervention to Improve Fear of Progression in Women With Gynecologic or Breast Cancer
  NCT07741968 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: Female · 11 locations
• A Navigation Program to Improve Survivorship Support Service Participation Among Non-metastatic Breast Cancer Survivors
  NCT07699991 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: Female · 1 location
• Acutherapy to Prevent Aromatase Inhibitor-Associated Arthralgias in Non-Hispanic Black Postmenopausal Women With Early-Stage Breast Cancer
  NCT06534125 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: Female · 4 locations
• Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
  NCT06058377 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 554 locations
• Breast Cancer Survivorship Biorepository
  NCT05786664 · Phase: Not specified · Ages: 18 Years and older · Sex: Female · 1 location
• Concurrent WOKVAC Vaccination, Chemotherapy, and HER2-Targeted Monoclonal Antibody Therapy Before Surgery for the Treatment of Patients With Breast Cancer
  NCT04329065 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer
  NCT02918474 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: Female · 1 location
• DiviTum®TKa: A Biomarker Assay for Efficacy in HR+ Breast Cancer Patients
  NCT06388122 · Phase: Not specified · Ages: 18 Years and older · Sex: Female · 1 location
• Dose-Reduced Docetaxel With Cyclophosphamide for the Treatment of Vulnerable Older Women With Stage I-III HER2 Negative Breast Cancer, the DOROTHY Trial
  NCT06042569 · Phase: Phase 2 · Ages: 65 Years and older · Sex: All (male and female) · 3 locations
• Enhancing Skin Appearance and Quality of Life in Breast Cancer Survivors on Aromatase Inhibitor Therapy
  NCT06401889 · Phase: Not specified · Ages: 18 Years and older · Sex: Female · 1 location
• Evaluation of Alternative Site Goserelin Acetate Injection for Ovarian Function Suppression (OFS) in Local and Locally Advanced Premenopausal Hormone Receptor Positive Breast Cancer Patients
  NCT07460752 · Phase: Phase 2 · Ages: 18 Years to 50 Years · Sex: Female · 1 location
• Feasibility Study of Biobehavioral Stress Reduction Intervention in Patients With Triple Negative Breast Cancer
  NCT05677802 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: Female · 2 locations
• Fisetin to Improve Physical Function in Stage I-III Breast Cancer Survivors
  NCT05595499 · Phase: Phase 2 · Ages: No age limits stated · Sex: Female · 7 locations
• Food for Thought - A Nutrition Intervention for Women Undergoing Active Treatment for Triple Negative Breast Cancer
  NCT06582615 · Phase: Not applicable (e.g. observational or device study) · Ages: 40 Years to 65 Years · Sex: Female · 2 locations
• Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer
  NCT06179303 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• Hypofractionated Radiotherapy Before or After Breast Surgery for Treatment of Patients With Non-Metastatic Breast Cancer
  NCT06635980 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Female · 1 location
• Imlunestrant and Abemaciclib for the Treatment of Estrogen Receptor Positive Breast Cancer in Patients With Minimal Residual Disease, MIRI Trial
  NCT07191717 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Immune Response to Anti-HER2 Therapies in Patients With HER2-Positive Stage I-IV Breast Cancer
  NCT04517838 · Phase: Not specified · Ages: 18 Years and older · Sex: Female · 1 location
• Leuprolide and Goserelin for Ovarian Function Suppression in Pre- or Peri-menopausal Women With Breast Cancer, OFS Trial
  NCT07158021 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Female · 1 location
• Lymphovenous Bypass Procedure Before Underarm Lymph Node Surgery in Preventing Lymphedema in Patients With Inflammatory or Locally Advanced Non-inflammatory Breast Cancer or Melanoma
  NCT03941756 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Metformin for the Treatment of Insulin Resistance in Women With Stage I-III Breast Cancer Completing Chemotherapy
  NCT06763328 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Female · 3 locations
• Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer
  NCT04090567 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Female · 1 location
• Personalized Exercise Program for Survivors of Breast Cancer, STEPS-BC Trial
  NCT07474090 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 85 Years · Sex: All (male and female) · 2 locations
• Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors
  NCT05269381 · Phase: Phase 1, Phase 2 · Ages: 16 Years and older · Sex: All (male and female) · 2 locations
• Personalized Vaccine Immunotherapy in Combination With Checkpoint Inhibitor for Treatment of Triple Negative Breast Cancer
  NCT06324240 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 4 locations
• Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax
  NCT05092373 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Prevention of Frailty With Fisetin and Exercise in Breast Cancer Survivors
  NCT06113016 · Phase: Phase 2 · Ages: No age limits stated · Sex: Female · 6 locations
• Propranolol and Pembrolizumab for Tumor Re-sensitization and Treatment of Patients With Checkpoint Inhibitor Refractory Metastatic or Unresectable Triple Negative Breast Cancer
  NCT05741164 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Female · 2 locations
• Remotely Delivered, Community-Aligned Weight Loss Interventions Among Breast Cancer Survivors, ¡Vida! Trial
  NCT05930483 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: Female · 1 location
• Tamoxifen and Pegylated Liposomal Doxorubicin for the Treatment of Patients With Metastatic or Inoperable, Locally Advanced Triple Negative Breast Cancer
  NCT06434064 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
  NCT05564377 · Phase: Phase 2 · Ages: No age limits stated · Sex: All (male and female) · 482 locations
• Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer
  NCT05422794 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 6 locations
• Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors
  NCT05372640 · Phase: Phase 1 · Ages: 12 Years and older · Sex: All (male and female) · 7 locations
• Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer
  NCT07137416 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• The Sleep After Breast Cancer (ABC) Study - Examining Sleep Changes and Biomarkers Among Breast Cancer Patients
  NCT07341503 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Time Restricted Eating for the Improvement of Outcomes in Patients With Stage I-III Breast Cancer Receiving Chemotherapy Before Surgery
  NCT05327608 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · 5 locations
• Topical or Oral Minoxidil for the Treatment of Endocrine Therapy-Induced Alopecia in Patients With Stage I-IV Breast Cancer
  NCT05417308 · Phase: Early Phase 1 · Ages: 18 Years and older · Sex: Female · 1 location
• Ultra-hypofractionated Whole Breast Irradiation With Lumpectomy Cavity Boost for the Treatment of Stage I-III Breast Cancer
  NCT06954831 · Phase: Phase 2 · Ages: 40 Years and older · Sex: Female · 7 locations

Related conditions

Trials recruiting for Anatomic Stage III Breast Cancer AJCC v8 often also study these conditions. Each links to its own recruiting-trial list.

Common questions

Are these trials free to join?

Study-related care in a clinical trial is usually provided at no cost to participants, and some trials reimburse travel. Costs vary by study - the trial team will explain what is and is not covered. Confirm this directly with them.

How do I know if I am eligible for Anatomic Stage III Breast Cancer AJCC v8 trials?

Each trial lists inclusion and exclusion criteria. The screener above checks stated age and sex only. The full eligibility (your medical history, current medications, test results) is assessed by the study team. Open any trial to read its criteria, then contact the site.

Is this list complete?

No. For the full list, search ClinicalTrials.gov.